Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Merck and Moderna announced positive Phase 3 INTerpath-001 results showing intismeran autogene plus KEYTRUDA reduced the risk of recurrence or death by 42% (HR=0.58, p<0.001) versus KEYTRUDA alone in resected stage IIB-IV melanoma. Distant metastasis-free survival also improved 38%, and a pre-specified analysis after six months showed a 58% reduction in recurrence risk. Two-year RFS was 82.2% versus 70.0% for control, with no new safety signals.
Key figures
- Drug Name
- intismeran autogene (V940 / mRNA-4157)
- Phase Of Trial
- Phase 3
- Dmfs hazard ratio
- 0.62
- Patients enrolled
- 1137
- Rfs risk reduction
- 42%
- Dmfs risk reduction
- 38%
- Median followup months
- 24.6
- Two year rfs rate control arm
- 70.0%
- Two year dmfs rate control arm
- 80.2%
- Piecewise hazard ratio after 6mo
- 0.42
- Two year rfs rate intismeran arm
- 82.2%
- Primary endpoint rfs hazard ratio
- 0.58
- Two year dmfs rate intismeran arm
- 88.5%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.